|
1
|
Liu G, Shi H, Zheng H, Kong W, Cheng X, Deng L. Circular RNA NFIX Functions as an Oncogene in Non-Small Cell Lung Cancer by Modulating the miR-214-3p/TRIAP1 Axis. THE CLINICAL RESPIRATORY JOURNAL 2024; 18:e13801. [PMID: 39135128 PMCID: PMC11319089 DOI: 10.1111/crj.13801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2024] [Revised: 06/05/2024] [Accepted: 06/12/2024] [Indexed: 08/15/2024]
Abstract
BACKGROUND circRNA NFIX has been shown to exist as an oncogene in glioma. But its expression and role in NSCLC (non-small cell lung cancer) are still unclear. This research aimed to discover the expression and function of circRNA NFIX in NSCLC. METHODS In this research, qRT-PCR was utilized to investigate the expression levels of circRNA NFIX, miRNA-214-3p, and TRIAP1 in NSCLC tissues and cell lines. The binding sites between circRNA NFIX/TRIAP1 and miRNA-214-3p were predicted using the Starbase. These interactions were further validated using a double luciferase reporter assay. Cell proliferation and apoptosis were assessed through MTT and flow cytometry, respectively. The expression of apoptosis-related proteins was measured by western blot assay. RESULTS miRNA-214-3p could link with circRNA NFIX. circRNA NFIX was upregulated, while miRNA-214-3p was downregulated in NSCLC cell lines and clinical samples. Besides, suppression of circRNA NFIX repressed cell proliferation and induced apoptosis in NSCLC cells by upregulating miRNA-214-3p expression. Besides, the data indicated that TRIAP1 was a target of miRNA-214-3p, and it was negatively regulated by miRNA-214-3p in NSCLC cells. The excessive expression of miRNA-214-3p suppressed NSCLC cell proliferation and increased apoptosis. In addition, overexpression of TRIAP1 significantly reversed the effects on NSCLC cells caused by miRNA-214-3p mimic. CONCLUSION circRNA NFIX silencing repressed the proliferation of NSCLC cells and induced cell apoptosis by regulating the miR-214-3p/TRIAP1 axis, which was a potential diagnostic and therapeutic target for NSCLC.
Collapse
Affiliation(s)
- Guohua Liu
- Department of Respiratory and Critical Care MedicineThe Third Affiliated Hospital of Qiqihar Medical CollegeQiqiharChina
| | - Hanbing Shi
- Department of Respiratory and Critical Care MedicineThe Third Affiliated Hospital of Qiqihar Medical CollegeQiqiharChina
| | - Hongyan Zheng
- Department of Respiratory and Critical Care MedicineThe Third Affiliated Hospital of Qiqihar Medical CollegeQiqiharChina
| | - Weili Kong
- Department of Respiratory and Critical Care MedicineThe Third Affiliated Hospital of Qiqihar Medical CollegeQiqiharChina
| | - Xinyue Cheng
- Department of Respiratory and Critical Care MedicineThe Third Affiliated Hospital of Qiqihar Medical CollegeQiqiharChina
| | - Liling Deng
- Department of PediatricsThe Third Affiliated Hospital of Qiqihar Medical CollegeQiqiharChina
| |
Collapse
|
|
2
|
Song C, Jung D, Kendi AT, Rho JK, Kim EJ, Horn I, Curran GL, Ghattamaneni S, Shim JY, Kang PS, Kang D, Thakkar JB, Dewan S, Lowe VJ, Lee SB. Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via FOXA1 Inhibition. Int J Mol Sci 2024; 25:7494. [PMID: 39000600 PMCID: PMC11242876 DOI: 10.3390/ijms25137494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Revised: 07/04/2024] [Accepted: 07/05/2024] [Indexed: 07/16/2024] Open
Abstract
Women with type 2 diabetes (T2D) have a higher risk of being diagnosed with breast cancer and have worse survival than non-diabetic women if they do develop breast cancer. However, more research is needed to elucidate the biological underpinnings of these relationships. Here, we found that forkhead box A1 (FOXA1), a forkhead family transcription factor, and metformin (1,1-dimethylbiguanide hydrochloride), a medication used to treat T2D, may impact hormone-receptor-positive (HR+) breast cancer (BC) tumor cell growth and metastasis. Indeed, fourteen diabetes-associated genes are highly expressed in only three HR+ breast cancer cell lines but not the other subtypes utilizing a 53,805 gene database obtained from NCBI GEO. Among the diabetes-related genes, FOXA1, MTA3, PAK4, FGFR3, and KIF22 were highly expressed in HR+ breast cancer from 4032 breast cancer patient tissue samples using the Breast Cancer Gene Expression Omnibus. Notably, elevated FOXA1 expression correlated with poorer overall survival in patients with estrogen-receptor-positive/progesterone-receptor-positive (ER+/PR+) breast cancer. Furthermore, experiments demonstrated that loss of the FOXA1 gene inhibited tumor proliferation and invasion in vitro using MCF-7 and T47D HR+ breast cancer cell lines. Metformin, an anti-diabetic medication, significantly suppressed tumor cell growth in MCF-7 cells. Additionally, either metformin treatment or FOXA1 gene deletion enhanced tamoxifen-induced tumor growth inhibition in HR+ breast cancer cell lines within an ex vivo three-dimensional (3D) organoid model. Therefore, the diabetes-related medicine metformin and FOXA1 gene inhibition might be a new treatment for patients with HR+ breast cancer when combined with tamoxifen, an endocrine therapy.
Collapse
Affiliation(s)
- Christine Song
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
- Harvard University, Cambridge, MA 02138, USA
| | - Dawa Jung
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Ayse Tuba Kendi
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Jin Kyung Rho
- Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea;
| | - Eun-Joo Kim
- Department of Molecular Biology, Dankook University, Cheonan 31116, Chungcheongnam, Republic of Korea;
| | - Ian Horn
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Geoffry L. Curran
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Sujala Ghattamaneni
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Ji Yeon Shim
- College of Nursing, Dankook University, Cheonan 31116, Chungcheongnam, Republic of Korea;
| | - Pil Soo Kang
- U&Hang Clinic, Asan 31514, Chungcheongnam, Republic of Korea;
| | - Daehun Kang
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Jay B. Thakkar
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Sannidhi Dewan
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Val J. Lowe
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
| | - Seung Baek Lee
- Division of Radiology, Mayo Clinic, Rochester, MN 55905, USA; (C.S.); (D.J.); (A.T.K.); (I.H.); (G.L.C.); (S.G.); (D.K.); (J.B.T.); (S.D.)
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
| |
Collapse
|
|
3
|
Singh S, Kaushik AC, Gupta H, Jhinjharia D, Sahi S. Identification of Prognostic Markers and Potential Therapeutic Targets using Gene Expression Profiling and Simulation Studies in Pancreatic Cancer. Curr Comput Aided Drug Des 2024; 20:955-973. [PMID: 37711100 DOI: 10.2174/1573409920666230914100826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 07/07/2023] [Accepted: 08/08/2023] [Indexed: 09/16/2023]
Abstract
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) has a 5-year relative survival rate of less than 10% making it one of the most fatal cancers. A lack of early measures of prognosis, challenges in molecular targeted therapy, ineffective adjuvant chemotherapy, and strong resistance to chemotherapy cumulatively make pancreatic cancer challenging to manage. OBJECTIVE The present study aims to enhance understanding of the disease mechanism and its progression by identifying prognostic biomarkers, potential drug targets, and candidate drugs that can be used for therapy in pancreatic cancer. METHODS Gene expression profiles from the GEO database were analyzed to identify reliable prognostic markers and potential drug targets. The disease's molecular mechanism and biological pathways were studied by investigating gene ontologies, KEGG pathways, and survival analysis to understand the strong prognostic power of key DEGs. FDA-approved anti-cancer drugs were screened through cell line databases, and docking studies were performed to identify drugs with high affinity for ARNTL2 and PIK3C2A. Molecular dynamic simulations of drug targets ARNTL2 and PIK3C2A in their native state and complex with nilotinib were carried out for 100 ns to validate their therapeutic potential in PDAC. RESULTS Differentially expressed genes that are crucial regulators, including SUN1, PSMG3, PIK3C2A, SCRN1, and TRIAP1, were identified. Nilotinib as a candidate drug was screened using sensitivity analysis on CCLE and GDSC pancreatic cancer cell lines. Molecular dynamics simulations revealed the underlying mechanism of the binding of nilotinib with ARNTL2 and PIK3C2A and the dynamic perturbations. It validated nilotinib as a promising drug for pancreatic cancer. CONCLUSION This study accounts for prognostic markers, drug targets, and repurposed anti-cancer drugs to highlight their usefulness for translational research on developing novel therapies. Our results revealed potential and prospective clinical applications in drug targets ARNTL2, EGFR, and PI3KC2A for pancreatic cancer therapy.
Collapse
Affiliation(s)
- Samvedna Singh
- School of Biotechnology, Gautam Buddha University, Greater Noida, India
| | | | - Himanshi Gupta
- School of Biotechnology, Gautam Buddha University, Greater Noida, India
| | - Divya Jhinjharia
- School of Biotechnology, Gautam Buddha University, Greater Noida, India
| | - Shakti Sahi
- School of Biotechnology, Gautam Buddha University, Greater Noida, India
| |
Collapse
|
|
4
|
Chen Y, Luo Y, Tian Q, Zeng D. miR-103 Derived from Bone Marrow Mesenchymal Stem Cell (BMSC) Retards the Chemo-Resistance Through Targeted-Regulation of TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) in Breast Cancer. J BIOMATER TISS ENG 2022. [DOI: 10.1166/jbt.2022.3018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The chemo-resistance was one of the major reasons for the treatment failure for breast cancer. Our study aimed to discuss the action of miR-103 derived from BMSC on retarding the chemo-resistance through targeted-regulating TRIAP1 in breast cancer. The cisplatin-resistant breast cancer
cells were cultivated and transfected with si-RNA targeting miR-103 followed by analysis of cell invasion, migration and apoptosis by Transwell. MiR-103 target gene was analyzed with bioinformatics method and dual-luciferase reporter assay. TRIAP1 expression was measured by Western Blot. The
cell apoptosis was reduced when miR-103 expression was restrained along with enhanced cell proliferation. The co-cultivation with BMSC in vitro could upregulate TRIAP1 expression in breast cancer cells. In cells transfected with si-miR-103, the expression of TRIAP1 was reduced, cell
apoptosis was increased and invasion was decreased. In conclusion, the chemo-resistance is induced and the malignant invasion of breast cancer cells is retarded by co-cultivation with mikR-103 derived from BMSC which might be through regulating the expression of TRIAP.
Collapse
Affiliation(s)
- Yihua Chen
- Department of Pathology, The General Hospital of Western Military Command, Chengdu, Sichuan, 610000, China
| | - Yan Luo
- Department of Pathology, The General Hospital of Western Military Command, Chengdu, Sichuan, 610000, China
| | - Qiang Tian
- Department of Pathology, The General Hospital of Western Military Command, Chengdu, Sichuan, 610000, China
| | - Dongmei Zeng
- Department of Pathology, The General Hospital of Western Military Command, Chengdu, Sichuan, 610000, China
| |
Collapse
|
|
5
|
Arman T, Baron JA, Lynch KD, White LA, Aldan J, Clarke JD. MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period. Toxicology 2021; 464:153021. [PMID: 34740672 PMCID: PMC8629135 DOI: 10.1016/j.tox.2021.153021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 10/08/2021] [Accepted: 10/29/2021] [Indexed: 12/30/2022]
Abstract
Nonalcoholic steatohepatitis (NASH) causes liver extracellular matrix (ECM) remodeling and is a risk factor for fibrosis and hepatocellular carcinoma (HCC). Microcystin-LR (MCLR) is a hepatotoxin produced by fresh-water cyanobacteria that causes a NASH-like phenotype, liver fibrosis, and is also a risk factor for HCC. The focus of the current study was to investigate and compare hepatic recovery after cessation of MCLR exposure in healthy versus NASH animals. Male Sprague-Dawley rats were fed either a control or a high fat/high cholesterol (HFHC) diet for eight weeks. Animals received either vehicle or 30 μg/kg MCLR (i.p: 2 weeks, alternate days). Animals were euthanized at one of three time points: at the completion of the MCLR exposure period and after 2 and 4 weeks of recovery. Histological staining suggested that after four weeks of recovery the MCLR-exposed HFHC group had less steatosis and more fibrosis compared to the vehicle-exposed HFHC group and MCLR-exposed control group. RNA-Seq analysis revealed dysregulation of ECM genes after MCLR exposure in both control and HFHC groups that persisted only in the HFHC groups during recovery. After 4 weeks of recovery, MCLR hepatotoxicity in pre-existing NASH persistently dysregulated genes related to cellular differentiation and HCC. These data demonstrate impaired hepatic recovery and persistent carcinogenic changes after MCLR toxicity in pre-existing NASH.
Collapse
Affiliation(s)
- Tarana Arman
- Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, United States
| | - J Allen Baron
- Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, United States
| | - Katherine D Lynch
- Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, United States
| | - Laura A White
- Washington Animal Disease Diagnostic Laboratory, Washington State University, Pullman, WA, 99164, United States
| | - Johnny Aldan
- Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, United States
| | - John D Clarke
- Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, United States.
| |
Collapse
|